Site map
An overview of the available content on this site. Keep the pointer still over an item for a few seconds to get its description.
- Why is this research being done?
- What is the purpose of this study?
- Who is doing the study?
- Who is being included in the study?
- What happens next if I agree to be included in this study?
- What are the possible benefits of being in the study?
- What are the possible risks of being in the study?
- Can I stop the study treatment or my participation early?
- If I have any questions or problems, who can I call?
- What information do you hold about me and how do you keep it private?
- Do I have to take part?
- Are there any financial costs or payments?
- What else can you tell me?
- What about my data privacy?
- Videos
- Pharmacy
- Site Set-Up
- Training
- site teams
- Follow-up data collection
- Randomisation
- Randomisation Training Confirmation
- Background & Consent Training Confirmation
- Children & Neonates Training Confirmation
- Convalescent Plasma Training Confirmation
- Monoclonal Antibodies Training Confirmation
- Oral Therapies Training Confirmation
- Follow-up Training Confirmation
- Oxford's COVID-19 research receives government funding
- First patients enrolled in new clinical trial of possible COVID-19 treatments
- Letter from Chief Medical Officers encourages participation in COVID-19 trials
- RECOVERY Trial rolled out across the UK
- RECOVERY team reflect on International Clinical Trials Day 2020
- Recruitment to the RECOVERY Trial continues as planned
- First patient, a child, receives convalescent plasma through RECOVERY, the dedicated COVID-19 treatment trial
- No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
- Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
- No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
- RECOVERY COVID-19 phase 3 trial to evaluate Regeneron’s REGN-COV2 investigational antibody cocktail in the UK
- Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19
- RECOVERY trial management acknowledged in clinical trial awards
- Statement on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial
- Update on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial
- Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
- RECOVERY participant is first person to receive and donate convalescent plasma
- RECOVERY trial clinicians can now be accredited through the Associate Principal Investigator Scheme